BackgroundSome experts have proposed combating rising drug prices by promoting brand–brand competition, a situation that is supposed to arise when multiple US Food and Drug Administration (FDA)-approved brand-name products in the same class are indicated for the same condition. However, numerous reports exist of price increases following the introduction of brand-name competition, suggesting that it may not be effective. We performed a systematic literature review of the peer-reviewed health policy and economics literature to better understand the interplay between new drug entry and intraclass drug prices.Methods and findingsWe searched PubMed and EconLit for original studies on brand–brand competition in the US market published in English between January 1990 and April 2019. We performed a qualitative synthesis of each study’s data, recording its primary objective, methodology, and results. We found 10 empirical investigations, with 1 study each on antihypertensives, anti-infectives, central nervous system stimulants for attention deficit/hyperactivity disorder, disease-modifying therapies for multiple sclerosis, histamine-2 (H2) blockers, and tumor necrosis factor (TNF) inhibitors; 2 studies on cancer medications; and 2 studies on all marketed or new drugs. None of the studies reported that brand–brand competition lowers list prices of existing drugs within a class. The findings of 2 studies suggest that such competition may help restrain how new drug prices are set. Other studies found evidence that brand–brand competition was mediated by the relative quality of competing drugs and the extent to which they are marketed, with safer or more effective new drugs and greater marketing associated with higher intraclass list prices. Our investigation was limited by the studies’ use of list rather than net prices and the age of some of the data.ConclusionsOur findings suggest that policies to promote brand–brand competition in the US pharmaceutical market, such as accelerating approval of non-first-in-class drugs, will likely not result in lower drug list prices absent additional structural reforms.

This dataset contains comprehensive retail price information for essential medicines and drug formulations in India, sourced directly from the National Pharmaceutical Pricing Authority (NPPA). The data has been meticulously scraped and cleaned to ensure accuracy and usability for various analytical purposes.

Key Features of the Dataset:

Medicine Salt: Generic names of the active pharmaceutical ingredients. Dosage Form & Strength: Details on the form (e.g., Tablet, Capsule, Injection) and the strength of the medicine (e.g., 300 mg, 10%). Retail Price per Unit: The regulated retail price per unit (e.g., per tablet, per ml) of the medicine. NLEM Year: The year corresponding to the National List of Essential Medicines (NLEM) framework under which the price was set. Potential Use Cases:

This dataset is ideal for:

Analyzing Medicine Pricing Trends: Explore how prices of specific medicines or categories have evolved over time. Healthcare Policy Research: Gain insights into drug price regulation and its impact on the pharmaceutical market in India. Supply Chain Analysis: Understand pricing structures across different formulations and strengths. Public Health Studies: Investigate accessibility and affordability of essential medicines. Educational Purposes: A valuable resource for learning data cleaning, exploratory data analysis (EDA), and data visualization techniques on real-world pharmaceutical data. The data provides a crucial snapshot of India's regulated medicine pricing landscape, offering valuable insights for researchers, analysts, and policymakers.

This is the first publicly available dataset of pharmaceutical prices in Pakistan. The dataset contains the maximum retail prices of medicines as set by the government in June 2021. It covers a wide range of drugs, including both branded and generic medications across various therapeutic categories. The data has been obtained from official government publications and price lists.

By analyzing this dataset, fellow data analysts can gain insights into the pricing trends and patterns of different drugs in Pakistan. The dataset can help researchers and public health experts to study the affordability and accessibility of essential medicines in Pakistan. The dataset can also be used by market analysts to track the performance of different pharmaceutical companies in the region. Furthermore, the dataset can be used to develop predictive models for drug prices, which could be valuable for both manufacturers and consumers. Overall, this dataset provides a unique opportunity for researchers and analysts to investigate the pricing dynamics of the pharmaceutical industry in Pakistan.

Study design We conducted a cross-sectional study to quantify the number and describe the characteristics of prescription drugs on the Canadian market as of August 23, 2022 with a patient support program defined as services (including but not limited to financial assistance) offered to patients prescribed a specific drug and initiated and funded by the manufacturer. We then conducted a structured content analysis of web-based sources to understand the types and range of supports provided to patients through these programs. We chose to rely exclusively on publicly available data sources to both identify and describe manufacturer-sponsored patient support programs as these are sources currently available to patients when making program enrolment decisions and policymakers seeking to understand the extent and impact of this model of care. Sampling frame Because the European Medicines Association defines a patient support program as services for a specific drug offered by the company holding the marketing authorization, we first sought to identify all drug companies with currently marketed, prescription products in Canada. Between June 27, 2022 and August 23, 2022, two investigators independently extracted the names of all member companies listed on the websites of the three main trade associations for the Canadian pharmaceutical industry (Innovative Medicines Canada, representing the research-based pharmaceutical industry; BIOTECanada, representing the biotechnology industry; and the Canadian Generic Pharmaceutical Association, representing generic drug manufacturers). Because trade association membership is voluntary, we supplemented this list with non-member drug manufacturers identified in previous research. Using the Health Canada Drug Product Database,two investigators independently screened the list of companies and included those with marketed, prescription products and excluded companies that were not drug manufacturers (e.g., law firms) or without currently marketed prescription drugs (e.g., products under development). Discrepancies were resolved through discussion or adjudication by a third author. Sample and variables Using the Health Canada Drug Product Database, one investigator searched each identified drug manufacturer and extracted the product and active ingredient name(s) for all marketed, prescription drugs. We counted a single “drug” as all dosages, formulations, or routes of administration with the same active ingredients and manufacturer since industry patient support programs are brand-specific and do not typically differentiate among these factors. We selected variables that reflect known characteristics of drugs that may be associated with having a patient support program, and for which data were publicly available. One investigator also extracted Schedule D (biologic) status, route(s) of administration, and Level 1 Anatomical Therapeutic Chemical (ATC) code from the Drug Product Database and Product Monograph and identified whether the drug had Orphan Drug Status using the searchable United States database. On the basis of type of Health Canada regulatory review (i.e. innovator or subsequent entry), clinical expertise, and knowledge about the manufacturer, two investigators independently identified the brand status of each drug as brand (i.e. “innovator” products first to market); branded generic (i.e. “subsequent entry” products which are bioequivalent or biosimilar to an existing product on the market, but given a proprietary name); or generic (i.e. “subsequent entry” products which are bioequivalent to an existing product on the market). We classified biosimilars as branded generics. We resolved discrepancies through discussion, and/or adjudication by a third author. Identifying patient support programs and their characteristics Our primary outcome was whether a sampled drug had an associated manufacturer-sponsored patient support program. We defined a patient support program as any combination of services or resources related to medication access, administration, adherence, education, storage, or disposal for patients prescribed a specific product and initiated, sponsored and/or operated by the company holding the product’s marketing authorization. We distinguished patient support programs from “patient assistance programs,” excluding programs that exclusively provided financial assistance (e.g., coupons, co-pay coverage, etc.); expanded or compassionate access programs; risk management programs outlined in the Product Monograph (initiated by the regulator rather than the manufacturer); and programs delivered solely for a clinical study. Two investigators independently performed structured searches on Google (“[company name] AND patient support program AND Canada” and “[drug brand name] AND patient support program AND Canada”) to identify industry sponsored patient support programs in Canada and resolving discrepancies through discussion. Using Zotero, a reference management...

According to a recent study, the average retail price for non-prescription drugs in Italy was *** euros per package. This statistic shows how this figure varied according to sales channel. Non-prescription drugs seemed to be most expensive in pharmacies, where a package had an average cost of **** euros. Conversely, large-scale retail was the cheapest sales channel, with non-prescription drugs holding an average price of *** euros per package.

The graph illustrates the most expensive drugs in the United States for the year 2024. The x-axis lists the drug names, including Lenmeldy***, Hemgenix*, Elevidys*, Skysona*, Zynteglo*, Zolgensma*, Myalept**, Danyelza**, Zokinvy**, and Kimmtrak**, while the y-axis represents the cost of each drug in U.S. dollars. Among these, Lenmeldy*** stands as the most costly medication at $4,250,000, followed by Hemgenix* at $3,500,000 and Elevidys* at $3,200,000. The prices gradually decrease with Skysona* priced at $3,000,000, Zynteglo* at $2,800,000, and Zolgensma* at $2,100,000. The remaining drugs—Myalept** ($1,300,000), Danyelza** and Zokinvy** (each at $1,200,000), and Kimmtrak** ($1,100,000)—are comparatively less expensive but still among the highest-priced medications available. The data reveals a significant disparity in drug costs, with the top-priced drug being nearly four times more expensive than the least expensive one listed. This steep decline from the highest to the lowest cost highlights the wide range of prices within the most expensive pharmaceuticals in the U.S. for 2024. The information is effectively represented in a bar graph format, which clearly showcases the differences in drug prices and emphasizes the concentration of costs among the top-tier medications.

Studies included in the systematic review.

Adjustment of drug prices after the change of their clinical status in the current drug pricing system in Japan functions as an appropriate allocation mechanism for drug expenditures under the universal health insurance system. However, the failure to incorporate a drug’s value when determining its price decreases pharmaceutical companies’ motivation to develop and launch novel drugs in Japan. In this study, we applied the value-based pricing framework MARIE to drugs with new clinical status. We estimated drug prices at the time of approval for the initial indication and new clinical status, with a total of 32 drugs by using MARIE. To estimate maximum number of patients for the new clinical status, we referred to the market expansion rate and calculated it backwards. As a result, the median change of MARIE-estimated price under new clinical status against those under initial indication was −50.24% (range, −80.36% to 16.39%). For the initial indication, the median ratio of the drug price estimated with MARIE to the initial list price was 122.12% (range, 15.57% to 2237.38%); the median ratio of actual to estimated drug price were similar to those in our previous study (125.65%). We proposed the versatile, practical, convenient, multiple criteria, qualitative VBP framework MARIE for the new clinical status. Under the MARIE system, price would only be changed when the “box” (category of the maximum number of patients) in the conversion table of the maximum number of the patients changes as the environment changes.

The Pharmacy Benefit Manager (PBM) market is booming, projected to reach $628.78 billion by 2033 with a 7.4% CAGR. This in-depth analysis explores market drivers, trends, restraints, key players (Express Scripts, CVS Health, etc.), and regional breakdowns, providing valuable insights for investors and industry professionals. Learn more about PBM market size, growth, and future projections.

According to a recent study, the average retail price in pharmacies for pharmaceutical drugs in Italy was *** euros per package in 2023. This statistic shows how this figure varied according to the different categories of drugs and products sold in pharmacies. Health supplements were the most expensive category, with an average price of **** euros. Herbal and homeopathic products followed, with average prices of **** euros and **** euros, respectively. This figure shows the average price of pharmaceutical drugs and products sold in pharmacies in Italy in 2023.

While smaller in scale than their US counterparts, brand-name pharmaceutical manufacturers in Canada play a pivotal role in the healthcare system. Canadians rely heavily on prescription medications, ranking among the highest globally in per capita drug spending. This positions manufacturers to benefit from strong consumer demand and public health initiatives. Recent drivers of increased spending on brand-name drugs include an aging population, broader health coverage through provincial plans, new therapy approvals and advances in specialized treatments for rare genetic disorders and cancer. Despite these tailwinds, branded manufacturers have struggled against rising biosimilar and generic competition, which offer more affordable options. In 2021, industry revenue dropped sharply, erasing gains from previous years. The leading causes included major patent expiries, stronger competition from generics and biosimilars, pandemic-related disruptions to healthcare services and rising operating expenses outpacing revenue growth. As a result, revenue has declined at a CAGR of 2.6% over the past five years, reaching an estimated $8.3 billion, despite expected growth of 1.8% in 2025. Regulatory pressures have continued to intensify in 2025, with the Patent Medicine Prices Review Board (PMPRB) implementing stricter price controls. New rules require drug list prices to be set at or below the lowest among PMPRB11 countries, with annual reassessments and more transparent discount reporting. These reforms align with international trends, forcing brand-name manufacturers to adjust their pricing and launch strategies. At the same time, the federal and provincial governments continue to support domestic pharmaceutical research and development (R&D) and supply chain resilience, particularly for innovative and rare disease treatments. Notably, specialty drugs and biopharmaceuticals continue to drive spending, including new approvals in oncology and for rare diseases in 2025. Meanwhile, public and private investment fuels research in biologics, gene therapies and precision medicine. Despite mounting pressure on prices and reimbursement, steady investments in research, an aging population and strong government support are keeping the market on a positive path. Pharmaceutical companies are consolidating and diversifying their drug pipelines to offset challenges from patent cliffs, regulatory complexity and increased competition from generics and biosimilars. New products, especially in areas related to cancer and rare diseases, will help brand-name pharmaceuticals maintain a strong, if evolving, role in Canada. Revenue for brand-name pharmaceutical manufacturers is expected to grow at a CAGR of 2.2%, reaching $9.3 billion by 2030 as demographic trends and advances in medicine drive continued demand.

According to a study conducted in 2024, Argentina had the highest price of medicines among seven countries in Latin America, with an average price of **** U.S. dollars. Colombia ranked second, with **** U.S. dollars. As of that year, Peru and Ecuador showed the lowest values, with an average of **** and *** U.S. dollars, respectively. Consumption trends and market growth The pharmaceutical sector in Latin America is experiencing consistent growth. In 2023, the region consumed an estimated *** billion defined daily doses of medicines, with projections indicating this will surpass *** billion doses by 2028. This increase in consumption aligns with forecasts for the pharmaceutical market's revenue, expected to reach approximately ** billion U.S. dollars by 2028. This represents an increase of approximately ** percent in comparison to 2023. Purchase channels Despite the growth of e-commerce in the pharmaceutical sector, traditional purchase channels remain dominant in Latin America. A 2023 survey found that local pharmacies are the preferred option for medication purchases, with about ** percent of respondents having bought medicines from these outlets in the previous year. However, the use of retail stores and online options varies significantly between countries. For instance, while only ***** percent of Brazilian consumers used retail stores for medicine purchases, this figure rose to ** percent in Colombia.

Prescription Price Comparison Platforms Market Outlook

According to our latest research, the global prescription price comparison platforms market size reached USD 2.4 billion in 2024, reflecting a robust surge in consumer demand for transparency in pharmaceutical pricing. The sector is experiencing a strong growth trajectory, with a recorded CAGR of 12.8% during 2024, and is forecasted to reach USD 7.1 billion by 2033. This impressive expansion is mainly driven by the increasing digitalization of healthcare services, growing consumer awareness about prescription drug costs, and the need for cost-containment strategies among healthcare stakeholders. As per our latest analysis, these factors are collectively propelling the adoption and evolution of prescription price comparison platforms worldwide.

One of the primary growth drivers for the prescription price comparison platforms market is the heightened demand for cost transparency in the pharmaceutical sector. Consumers are increasingly seeking solutions that allow them to compare drug prices across various pharmacies, aiming to mitigate the financial burden associated with prescription medications. The proliferation of high-deductible health plans and rising out-of-pocket expenses have further accentuated the need for accessible and user-friendly platforms. As a result, more individuals are turning to digital tools that empower them to make informed decisions regarding their healthcare expenditures. This shift in consumer behavior is compelling both established healthcare entities and new entrants to invest in and enhance prescription price comparison technologies, thereby fueling market growth.

Another significant factor contributing to market expansion is the integration of advanced technologies such as artificial intelligence, machine learning, and big data analytics within these platforms. These technological advancements enable platforms to deliver real-time, personalized pricing information, and enhance user experience through predictive analytics and tailored recommendations. Moreover, partnerships between price comparison platforms and pharmacy benefit managers (PBMs), insurance companies, and retail pharmacies are becoming increasingly common, resulting in broader data access and improved pricing accuracy. Such collaborations not only streamline the prescription fulfillment process but also foster trust among users, further accelerating market penetration and adoption rates.

The growing emphasis on regulatory compliance and healthcare interoperability is also catalyzing the growth of the prescription price comparison platforms market. Governments and regulatory bodies in several regions are advocating for greater price transparency and patient empowerment, introducing policies that encourage the use of digital health tools. For instance, initiatives such as the U.S. Centers for Medicare & Medicaid Services’ price transparency rules are creating a favorable environment for the proliferation of these platforms. Additionally, the ongoing digital transformation of healthcare infrastructure, coupled with the widespread adoption of electronic health records (EHRs), is facilitating seamless data integration and exchange, further supporting the scalability and effectiveness of prescription price comparison solutions.

Regionally, North America remains the dominant force in the prescription price comparison platforms market, accounting for the largest share in 2024. The region’s advanced healthcare ecosystem, high digital literacy rates, and proactive regulatory measures have fostered an environment conducive to innovation and adoption. Europe follows closely, driven by increasing healthcare expenditures and a growing focus on patient-centric care models. Meanwhile, the Asia Pacific region is witnessing rapid growth, fueled by expanding internet penetration, rising healthcare costs, and a burgeoning middle-class population. Latin America and the Middle East & Africa, while still emerging markets, are showing promising potential due to accelerating digital transformation and increasing awareness of healthcare affordability.

Platform Type Analysis

The platform type segment in the prescription price comparison platforms market is primarily categorized into web-based platforms, mobile applications, and others. Web-based platforms have historically dominated the landscape, owing to their accessibility and comprehensive features. These platforms offer users the conveni

About the Dataset: Pharmaceutical Products Pricing and Availability Data in Pakistan

This dataset contains information about pharmaceutical product pricing and availability in Pakistan. The data was collected from various sources and compiled into a structured format for analysis. The dataset consists of 1630 entries with 7 columns, including:

Name: The name of the pharmaceutical product. Company: The company manufacturing or distributing the product. Price_before: The product's price before any discount is applied. Discount: The discount offered on the product, if applicable. Price_After: The price of the product after applying any discount. Pack_Size: The size or quantity of the product's packaging. Availability: The availability status of the product.

The dataset provides insights into the pricing trends and availability of pharmaceutical products in Pakistan, which can be valuable for various stakeholders including consumers, healthcare professionals, and policymakers. It can be used for analysis, research, and decision-making in the pharmaceutical industry.

Data Overview: Entries: 1630 Missing Values: Some columns have missing values, such as 'Name', 'Company', 'Price_before', 'Discount', 'Price_After', 'Pack_Size', and 'Availability'. Data Types: The dataset consists of object types for textual data and one float type for numerical data.

Potential Uses: This dataset can be used for a variety of purposes, including:

• Analyzing pricing trends and patterns of different drugs in Pakistan.
• Studying the affordability and accessibility of essential medicines in Pakistan.
• Tracking the performance of different pharmaceutical companies in the Pakistani market.
• Identifying potential areas for improving access to affordable medicines in Pakistan.

Limitations: It is important to note that this dataset only includes data on the maximum retail prices of pharmaceutical products. The actual price consumers pay may vary depending on the pharmacy and other factors. Additionally, the dataset does not include information on the quality of the pharmaceutical products.

I hope this description is helpful!

BackgroundThe high cost of prescription drugs in the United States is maintained by brand-name manufacturers’ competition-free period made possible in part through patent protection, which generic competitors must challenge to enter the market early. Understanding the predictors of these challenges can inform policy development to encourage timely generic competition. Identifying categories of drugs systematically overlooked by challengers, such as those with low market size, highlights gaps where unchecked patent quality and high prices persist, and can help design policy interventions to help promote timely patient access to generic drugs including enhanced patent scrutiny or incentives for challenges. Our objective was to characterize and assess the extent to which market size and other drug characteristics can predict patent challenges for brand-name drugs.Methods and findingsThis cross-sectional study included new patented small-molecule drugs approved by the FDA from 2007 to 2018. Market size, patent, and patent challenge data came from IQVIA MIDAS pharmaceutical quarterly sales data, the FDA’s Orange Book database, and the FDA’s Paragraph IV list. Predictive models were constructed using random forest and elastic net classification. The primary outcome was the occurrence of a patent challenge within the first year of eligibility. Of the 210 new small-molecule drugs included in the sample, 55% experienced initiation of patent challenge within the first year of eligibility. Market value was the most important predictor variable, with larger markets being more likely to be associated with patent challenges. Drugs in the anti-infective therapeutic class or those with fast-track approval were less likely to be challenged. The limitations of this work arise from the exclusion of variables that were not readily available publicly, will be the target of future research, or were deemed beyond the scope of this project.ConclusionsGeneric competition does not occur with the same timeliness across all drug markets, which can leave granted patents of questionable merit in place and sustain high brand-name drug prices. Predictive models may help direct limited resources for post-grant patent validity review and adjust policy when generic competition is lacking.

Hepatitis Drugs Market Outlook

According to our latest research, the global hepatitis drugs market size reached USD 18.7 billion in 2024, reflecting robust growth driven by the rising prevalence of hepatitis infections worldwide and advancements in antiviral therapeutics. The market is projected to expand at a CAGR of 4.6% from 2025 to 2033, reaching an estimated USD 28.1 billion by 2033. This steady growth is attributed to increasing awareness, improved diagnostic capabilities, and the introduction of innovative drug formulations targeting various hepatitis types. As per our latest research, the market’s upward trajectory is further bolstered by government initiatives and the growing adoption of combination therapies.

One of the primary growth factors for the hepatitis drugs market is the alarming rise in the incidence and prevalence of hepatitis infections, especially hepatitis B and hepatitis C. Globally, over 350 million people are estimated to live with chronic hepatitis B or C, creating a significant demand for effective antiviral therapies and immunomodulators. The persistent burden of these infections, particularly in low- and middle-income countries, has led to sustained investments in research and development by both public and private sectors. Additionally, the expansion of screening programs and improved disease awareness have contributed to early diagnosis and timely intervention, fueling the adoption of hepatitis drugs across hospital and retail pharmacies.

Another key driver is the continuous innovation in drug development, which has resulted in the launch of highly effective direct-acting antivirals (DAAs) and novel immunomodulatory agents. Pharmaceutical companies are increasingly focusing on developing pan-genotypic agents and fixed-dose combinations that offer higher cure rates, fewer side effects, and shorter treatment durations. These advancements have revolutionized the management of hepatitis C, in particular, enabling treatment of previously hard-to-treat populations and reducing the risk of liver-related complications such as cirrhosis and hepatocellular carcinoma. The growing pipeline of hepatitis therapeutics and the increasing number of regulatory approvals are expected to further propel market expansion over the forecast period.

Furthermore, favorable government policies and international collaborations play a pivotal role in driving the hepatitis drugs market. Initiatives such as the World Health Organization’s Global Health Sector Strategy on Viral Hepatitis and national hepatitis elimination programs have led to increased funding for hepatitis prevention, diagnosis, and treatment. Subsidized drug pricing, expanded insurance coverage, and the inclusion of hepatitis drugs in essential medicines lists have improved accessibility, particularly in emerging economies. These efforts, coupled with the rise in public-private partnerships and the strengthening of healthcare infrastructure, are expected to sustain the market’s growth momentum in the coming years.

From a regional perspective, North America currently dominates the hepatitis drugs market, accounting for the largest revenue share in 2024, followed by Europe and Asia Pacific. The high prevalence of hepatitis C, advanced healthcare infrastructure, and the availability of innovative therapies drive market growth in North America. However, Asia Pacific is anticipated to witness the fastest growth during the forecast period, supported by a large patient pool, increasing healthcare expenditure, and ongoing efforts to improve hepatitis screening and treatment rates. Latin America and the Middle East & Africa also present significant growth opportunities, driven by rising disease awareness and government-led hepatitis elimination campaigns.

Drug Class Analysis

The hepatitis drugs market is segmented by drug class into antiviral drugs, immunomodulators, vaccines, and others. Antiviral drugs represent the largest segment, primarily due to their critical role in the treatment of chronic hepatitis B and C infections. The introduction of direct-acting antivirals (DAAs) has transformed the hepatitis C treatment landscape, offering cure rates exceeding 95 percent with shorter therapy durations and minimal side effects. Pharmaceutical companies continue to invest in the development of next-generation antivirals that target multiple hepatitis virus genotypes, further expanding therapeutic options. The strong clinical efficacy, favorable safety profiles, and increasing adoption

Objective: To evaluate the impact of new national drug pricing policy (NDPP) 2018 on the access to medicines in terms of prices, availability, and affordability.

Design: Two cross-sectional surveys were undertaken before and after the launch of NDPP 2018, using a modified WHO/HAI methodology.

Setting: Four districts of Lahore division, Pakistan.Â

Participants: 16 public sector hospitals and 16 private sector retail pharmacies.

Measures: The pre- and post-survey data on prices and availability of Lowest Price Generics (LPGs) and Originator Brands (OBs) of 50 medicines were obtained by visiting the same public and private sector health facilities (n=32). Out of 50, 46 surveyed medicines were from National Essential Medicines List (NEML). Inflation-adjusted median unit prices (MUPs) and median price ratios (MPRs) from 2019 were used for price comparison. Affordability was calculated in terms of number of days’ wages required to get a standard treatment by the lowest paid uns...

Snapshot img

Generic Drugs Market Size 2025-2029

The generic drugs market size is forecast to increase by USD 217.4 billion, at a CAGR of 7.6% between 2024 and 2029.

The market is driven by the increasing demand for low-cost alternatives to branded medicines. This trend is particularly pronounced in developing economies where affordability is a significant factor in healthcare access. However, the market faces challenges, including the advent of Robotic Process Automation (RPA) in the pharmaceutical industry, which could potentially reduce the cost advantage of generic drugs. Additionally, rising credibility issues related to generic drugs pose a significant challenge, as consumers and healthcare providers increasingly demand assurance of quality and safety. Companies in the market must navigate these challenges by focusing on ensuring the highest standards of quality and safety, while also leveraging technological advancements to maintain cost competitiveness.
Strategic partnerships, mergers and acquisitions, and collaborations could also provide opportunities for market expansion and growth. Overall, the market presents both opportunities and challenges, requiring a strategic approach from market participants to capitalize on the former and mitigate the latter.

What will be the Size of the Generic Drugs Market during the forecast period?

Explore in-depth regional segment analysis with market size data - historical 2019-2023 and forecasts 2025-2029 - in the full report.
Request Free Sample

The market continues to evolve, shaped by various factors that impact its dynamics. Patient education plays a crucial role in ensuring the effective utilization of medications, with dosage forms varying from capsules to tablets and liquids. Clinical trials and pharmacokinetic studies contribute to regulatory approval, ensuring therapeutic equivalence and drug safety. Pharmaceutical manufacturing involves GMP compliance and stability testing to maintain quality, while patent expiration triggers increased competition and price reductions. Drug interactions necessitate diligent monitoring and education, with regulatory bodies such as the EMA and FDA overseeing approvals. Value-based healthcare and market access strategies prioritize cost-effectiveness analysis, influencing pricing and distribution channels.

Online pharmacies and retail pharmacies adapt to evolving market trends, offering convenience and accessibility. Intellectual property rights and pharmacy dispensing regulations shape the competitive landscape. Bioequivalence studies and drug utilization reviews facilitate generic substitution, while pharmacy dispensing and capsule filling processes ensure accurate and efficient prescription fulfillment. The continuous unfolding of market activities necessitates ongoing attention to drug safety, regulatory compliance, and pricing strategies.

How is this Generic Drugs Industry segmented?

The generic drugs industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Route Of Administration

  Oral
  Injectables
  Topical
  Inhalers


Type

  Small-molecule generics
  Biosimilars


Application

  Anti-infectives
  CNS
  Others


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

.

By Route Of Administration Insights

The oral segment is estimated to witness significant growth during the forecast period

The oral route of administration is the most commonly used. Oral administration is the ingestion of a drug through the mouth into the gastrointestinal tract. The oral drug delivery system market segment includes drugs that can be administered in the form of capsules, tablets, syrups, solutions, and suspensions. The growth of the segment is accelerating at a moderate pace due to the ease of usage and an increasing number of companies investing in research and development for oral treatment. The advantages provided by the oral route, such as better availability, rapid drug delivery, and high efficacy, are further expected to propel the growth of the oral segment, which, in turn, will drive the growth of the market during the forecast period.

Request Free Sample

The Oral segment was valued at USD 232.00 billion in 2019 and showed a gradual increase during the forecast period.

Regional Analysis

North America is estimated to contribute 33% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.

Request Free Sample

The market in North America is experiencing significant growth, with the Unit

Since its inception in the 1960s, the Pharmacy Benefit Management (PBM) industry has evolved into one of the most central players in the pharmaceutical supply chain in the US. Responsible for administering prescription drug benefits, PBM providers have grown in parallel with the leading drug manufacturers and health insurers in recent years as patients' use of pharmaceuticals has grown. Alongside this growth has come massive consolidation activity; horizontal integration over decades brought the number of PBMs down to 30 in 2016, with a spike in vertical integration activity in 2018 completely restructuring the industry. Today, the three leading PBMs are vertically integrated behemoths responsible for over 80.0% of all prescription claims in the US, on average. However, this vertical integration has captured the attention of regulators and policymakers concerned about anticompetitive practices and misaligned incentives. In all, revenue is forecast to expand at a CAGR of 5.6% to $638.0 billion through 2025, including expected growth of 8.6% in 2025 alone.Regulators' spotlight on PBMs' power to control what health plans and patients pay for prescription medications is growing. Legislation is pending in over 40 states to reform how PBMs operate, focusing on transparency on drug rebates from manufacturers and spread pricing. An antitrust probe into the PBM industry by the Federal Trade Commission is also ongoing. Challenges confronting the industry don't stop there, with emerging approaches to prescription drugs introducing pressures. Amazon Pharmacy's RxPass and Cost Plus Drugs sidestep the middleman and offer prescription drugs directly to consumers at cash rates. These pharmaceutical providers' transparency raises more questions about the leading PBMs' secrecy.Disruption building in the PBM industry in recent years will come to a head moving forward. While it remains uncertain how mounting concerns and FTC inquiries will shape the industry's future, they will undoubtedly change how PBMs operate. One trend expected to accelerate its disruption of the industry will be the growth of cash-pay pharmacies like CPD. Regardless, the role of PBMs will remain crucial in the pharma supply chain, with demand for generics and specialties expanding as the population ages. Revenue will continue growing, increasing at a CAGR of 1.4% through 2030 to reach an estimated $684.3 billion.